海思科：HSK44459片获得新增适应症临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HSK44459 tablets, which are aimed at treating inflammatory bowel disease, including ulcerative colitis and Crohn's disease [1] Group 1 - HSK44459 tablets are a new small molecule drug developed by the company specifically for inflammatory bowel disease [1] - Preclinical studies indicate that HSK44459 has a clear target, definite efficacy, and good safety profile, suggesting a broad clinical application potential [1] - The company will disclose information in a timely manner based on the progress of the project [1]